MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

MicroRNAs Levels in Women With Postmenopausal Osteoporosis Under Antiresorptive or Osteoanabolic Treatment

The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.

Primarily the influence of the therapeutic treatment on the microRNA concentration in the serum (treatment-response) and the relation between microRNA serum levels and changes of the bone mineral density will be investigated.

These data will help to examine the use of microRNAs as novel diagnostic biomarkers for the diagnosis of osteoporosis and targeted therapeutic treatment of patients.

Inclusion Criteria:

• Postmenopausal women
• Age 60-80 years
• T-score according to DXA: <-2.5
• indication for osteoporosis therapy according to international guidelines

Exclusion Criteria:

• Diabetes mellitus type 1
• renal insufficiency III-V °
• Cirrhosis hepatis (Child B or higher)
• Chronic alcohol abuse
• rheumatic disease (RA, SpA, SLE)
• Malignancies (<5 years)
• Eating Disorder (anorexia nervosa, bulimia)
• bone-specific pretreatment (DMAB, TPTD, strontium ranelate, SERMs) Bisphosphonate treatment is allowed